Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Argatroban in Acute Ischemic Stroke With Early Neurological Deterioration
NCT04275180Phase 4Completed
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Mar 2020
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of argatroban in ischemic stroke (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: modified Rankin Scale score <= 3 at 3 months. Started Mar 2020; status: completed.
02
Drugs
argatroban
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT04275180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04275180.